UZH-Logo

Maintenance Infos

Comparison of 2.5 mg/kg and 5 mg/kg systemic bevacizumab in neovascular age-related macular degeneration: twenty-four week results of an uncontrolled, prospective cohort study


Geitzenauer, W; Michels, S; Prager, F; Rosenfeld, P J; Kornek, G; Vormittag, L; Schmidt-Erfurth, U (2008). Comparison of 2.5 mg/kg and 5 mg/kg systemic bevacizumab in neovascular age-related macular degeneration: twenty-four week results of an uncontrolled, prospective cohort study. Retina, 28(10):1375-1386.

Abstract

Background: To compare safety, visual acuity (VA), and anatomic outcomes of 2.5 mg/kg and 5 mg/kg intravenous bevacizumab in patients with neovascular age-related macular degeneration.

Methods: In an institutional cohort study, 16 patients (2 cohorts, 27 eyes) with neovascular age-related macular degeneration were treated with 5 mg/kg intravenous bevacizumab and 2.5 mg/kg, respectively. All patients received 3 initial intravenous infusions at 2-week intervals. The main outcome measures were VA, optical coherence tomography, and fluorescein angiography.

Results: No serious systemic or ocular adverse events were identified. By Day 7, mean VA increased from 56 letters (20/80+1) at baseline to 60 letters (20/63) in the 5 mg/kg group and mean central retinal thickness decreased by 83 [mu]m. In the 2.5 mg/kg group, mean VA increased from 55 letters (20/80) to 66 letters (20/50+1) and mean central retinal thickness decreased by 93 [mu]m. By Month 3, VA improved by 10 letters compared to baseline in the 5 mg/kg group and by 9 letters in the 2.5 mg/kg group. Central retinal thickness was reduced by 128 [mu]m in the 5 mg/kg group and by 127 [mu]m in the 2.5 mg/kg group. These benefits were sustained through 6 months. No statistically significant difference was found between both treatment groups regarding safety, VA, and anatomic outcomes.

Conclusion: Similar VA, optical coherence tomography, and angiographic improvements were observed in both treatment groups up to 6 months. Further follow-up is required to evaluate the long-term durability and safety of both treatment regimens.

Background: To compare safety, visual acuity (VA), and anatomic outcomes of 2.5 mg/kg and 5 mg/kg intravenous bevacizumab in patients with neovascular age-related macular degeneration.

Methods: In an institutional cohort study, 16 patients (2 cohorts, 27 eyes) with neovascular age-related macular degeneration were treated with 5 mg/kg intravenous bevacizumab and 2.5 mg/kg, respectively. All patients received 3 initial intravenous infusions at 2-week intervals. The main outcome measures were VA, optical coherence tomography, and fluorescein angiography.

Results: No serious systemic or ocular adverse events were identified. By Day 7, mean VA increased from 56 letters (20/80+1) at baseline to 60 letters (20/63) in the 5 mg/kg group and mean central retinal thickness decreased by 83 [mu]m. In the 2.5 mg/kg group, mean VA increased from 55 letters (20/80) to 66 letters (20/50+1) and mean central retinal thickness decreased by 93 [mu]m. By Month 3, VA improved by 10 letters compared to baseline in the 5 mg/kg group and by 9 letters in the 2.5 mg/kg group. Central retinal thickness was reduced by 128 [mu]m in the 5 mg/kg group and by 127 [mu]m in the 2.5 mg/kg group. These benefits were sustained through 6 months. No statistically significant difference was found between both treatment groups regarding safety, VA, and anatomic outcomes.

Conclusion: Similar VA, optical coherence tomography, and angiographic improvements were observed in both treatment groups up to 6 months. Further follow-up is required to evaluate the long-term durability and safety of both treatment regimens.

Citations

10 citations in Web of Science®
13 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

4 downloads since deposited on 05 Dec 2008
0 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Ophthalmology Clinic
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2008
Deposited On:05 Dec 2008 14:27
Last Modified:05 Apr 2016 12:32
Publisher:Lippincott Wiliams & Wilkins
ISSN:0275-004X
Publisher DOI:10.1097/IAE.0b013e3181863f96
Official URL:http://www.retinajournal.com/pt/re/retina/abstract.00006982-200805000-00002.htm;jsessionid=J54LCBH9Kdf21KGcgLx8GhLL2VBDkq2yhK9G8jwqDvXFSyZwSX5l!273838506!181195628!8091!-1
PubMed ID:18784625
Permanent URL: http://doi.org/10.5167/uzh-5077

Download

[img]
Filetype: PDF - Registered users only
Size: 2MB
View at publisher

TrendTerms

TrendTerms displays relevant terms of the abstract of this publication and related documents on a map. The terms and their relations were extracted from ZORA using word statistics. Their timelines are taken from ZORA as well. The bubble size of a term is proportional to the number of documents where the term occurs. Red, orange, yellow and green colors are used for terms that occur in the current document; red indicates high interlinkedness of a term with other terms, orange, yellow and green decreasing interlinkedness. Blue is used for terms that have a relation with the terms in this document, but occur in other documents.
You can navigate and zoom the map. Mouse-hovering a term displays its timeline, clicking it yields the associated documents.

Author Collaborations